Slide 1: Welcome! Elekta ESTRO 2024
Welcome! Elekta ESTRO 2024 Glasgow May 4, 2024 Restricted Information and Basic Personal Data
Slide 2: Agenda
Agenda Strengthening our competitiveness through innovation and partnerships Gustaf Salford, President & CEO Personalized precision and elevated productivity Maurits Wolleswinkel, Head of Linac and Software Solutions and John Christodouleas MD, SVP Medical Affairs and Clinical Research Software driv
Slide 3: Welcome to Glasgow!
Welcome to Glasgow! Restricted Information and Basic Personal Data
Slide 4: Theme of ESTRO: The cancer burden gap is increasing – innovation is key!
Theme of ESTRO: The cancer burden gap is increasing – innovation is key! Cancer care professionals supply vs. demand Indicative What customers tell us: “We have doubled patient volumes and half the staff” How we help them close the cancer gap: We innovate to personalize precision and elevate product
Slide 5: We continue to deliver on our strategy – ACCESS 2025
We continue to deliver on our strategy to provide Access to the best cancer care – ACCESS 2025 Drive partner integration Accelerate innovation with A world across the cancer care eco- customer utilization in mind where everyone system has access to the best Be the customer lifetime cancer care Drive
Slide 6: We are driving 'Adaptive' across our entire portfolio and building out ONE
We are driving ‘Adaptive’ across our entire portfolio and continuously build out our ONE software suite … Adaptive across entire portfolio Personalized Precision Adaptive on Evo CMM with Unity SRS on Esprit Xoft Electronic (LGK) Brachytherapy Smart Workflows Outcomes NEW Planning (PRO) Elevated Prod
Slide 7: Opportunities for our large Elekta installed base
… offering great opportunities to our large Elekta installed base expanded globally during ACCESS 2025 Adaptive across entire portfolio Upgrades to installed base Adaptive on Evo CMM with Unity SRS on Esprit Xoft Electronic (LGK) Brachytherapy Smart Workflows Outcomes NEW Planning (PRO) ~ 7 300 devi
Slide 8: Customers' demand for adaptive treatments is increasing
Our customers’ demand for adaptive treatments is increasing – recent examples from April From LinkedIn Workflow efficiencies are realizing Evo ➢ 20 patients treated in one day in Australia – fully adapt-to-shape Online adaptive workflows to accelerate through Evo launch Adoption is increasing contin
Slide 9: Elekta's partnership ecosystem
Elekta’s partnership ecosystem Restricted Information and Basic Personal Data
Slide 10: Acquisition of Philips Healthcare's Pinnacle (TPS) patent portfolio
Acquisition of Philips Healthcare’s Pinnacle (TPS) patent portfolio “ Restricted Information and Basic Personal Data
Slide 11: Key topics
Key topics New innovation Unity adoption Wins in Europe Margin expansion Restricted Information and Basic Personal Data 10
Slide 12: Agenda
Agenda Strengthening our competitiveness through innovation and partnerships Gustaf Salford, President & CEO Personalized precision and elevated productivity Maurits Wolleswinkel, Head of Linac and Software Solutions John Christodouleas MD, SVP Medical Affairs and Clinical Research Software driving
Slide 13: We innovate for personalized precision, elevated productivity
We innovate for ‘personalized precision, elevated productivity’ to help our customers close the cancer burden gap Personalized Elevated Precision Productivity Further elevate precision Towards halving the total and outcomes cost per treatment AI-driven informatics integrated across Restricted Inform
Slide 14: We innovate for personalized precision, elevated productivity
We innovate for ‘personalized precision, elevated productivity’ to help our customers close the cancer burden gap Personalized Elevated Precision Productivity Elekta Evo Elekta ONE | Planning (Pro) Elekta Unity Restricted Information and Basic Personal Data 13
Slide 15: We innovate for personalized precision, elevated productivity
We innovate for ‘personalized precision, elevated productivity’ to help our customers close the cancer burden gap Personalized Elevated Precision Productivity Elekta Evo Elekta ONE | Planning (Pro) Elekta Unity Restricted Information and Basic Personal Data 14
Slide 16: 'Adaptive' will become the standard for personalization
Personalized Precision ‘Adaptive’ will become the standard for personalization 20s 80s-90s 00s-20s & Increasing 3D/IMRT IGRT Beyond personalization ART • Focus on improving • Imaging used to • Treatment plan delivery position patient continuously updated • Limited • Fixed treatment • Updates informe
Slide 17: New device innovations aimed at driving personalized precision
Personalized Precision Our new device innovations are aimed at driving ‘personalized precision’; personalization through both CT & MR-guided treatment Planning Treatment Delivery Review and outcome assessment Blocks of treatment fractions ~8 weeks Conventional IGRT treatment ~2-4 weeks Hypofractiona
Slide 18: Introducing Evo with Iris and Elekta ONE | Online
Personalized Precision Introducing Evo with Iris and Elekta ONE | Online Driving increasingly adaptive CT-guided treatments Image Quality Iris Elekta ONE | Online* *Elekta ONE | Planning, Planning Pro and Online are powered by MIM Restricted Information and Basic Personal Data
Slide 19: Current CT-Linac offerings
Personalized Precision Current CT-Linac offerings Evo alone provides both versatility and adaptivity without compromise Versatile Offline Online Upgradable from Offline Adaptive Adaptive to Online Adaptive Other workhorse Linacs Other existing C-arm Linacs Other Online Adaptive Linacs Elekta Evo Mar
Slide 20: Comprehensive Motion Management completes the Unity value proposition
Personalized Precision Comprehensive Motion Management completes the Unity value proposition and will accelerate commercial traction See targets invisible to CBCT Manage motion, non-invasively, anywhere in the body Images courtesy of (Advanced Radiation Oncology Department (ARO), IRCCS Ospedale “Sac
Slide 21: Now the only partner for the entire spectrum of RT interventions
Personalized Precision Now the ONLY PARTNER for the ENTIRE SPECTRUM of RT interventions Intensity of Intervention Evo Evo Evo Conventional Off-line Adaptive Stereotactic body radiation On-line Adaptive Brachytherapy therapy (SBRT) and Stereotactic radiosurgery(SRS) 20 Restricted Information and Basi
Slide 22: We innovate for personalized precision, elevated productivity
1 We innovate for ‘personalized precision, elevated productivity’ to help our customers close the cancer burden gap Personalized Elevated Precision Productivity Elekta Evo Elekta ONE | Planning (Pro) Elekta Unity Restricted Information and Basic Personal Data
Slide 23: Elekta ONE unifies our software with open interoperability
Elevated Productivity Similarly, Elekta ONE unifies our software while enabling feature evolution and open interoperability Workflow management Treatment applications Non-Elekta device Electronic Health interoperability MOSAIQ® record / pathway interoperability Integrated Console Real-world outcomes
Slide 24: New treatment applications support elevated productivity
Elevated Productivity Our new treatment applications support ‘elevated productivity’ and reassert commitment to open interoperability New Workflow NEW Treatment • Unified software management applications environment Non-Elekta device EHR1/pathway • Evolving ecosystem, no MOSAIQ® interoperability int
Slide 25: Elekta ONE | Planning, powered by MIM – what is it?
Elevated Productivity Elekta ONE | Planning, powered by MIM – what is it? Plan Anywhere Integration ➢ One server, multiple clients, ➢ Best of MIM Maestro and Elekta fully cloud ready Monaco integrated Speed ➢ Superior physician user experience, best plan quality ➢ Ultra-fast GPU-based dose planning
Slide 26: Treatment Planning IP bolstered by Philips patent acquisition
Elevated Productivity Elekta Treatment Planning intellectual property now bolstered by acquisition of Philips portfolio of patents ✓ Leverage Philips Pinnacle IP in Elekta ONE | Planning ✓ Make it easier for existing Pinnacle users to convert to Elekta ONE | Planning ✓ Continue to support Elekta and
Slide 27: Innovation focus leads to a compelling business case
Innovation focus leads to a compelling business case Strengthening Focusing on Building on Unity Vendor agnostic standalone software installed base Shorter time-to- value and high- margin upgrade potential Upselling higher recurring value per customer – Launch of first phase of CT- With Elekta ONE |
Slide 28: Agenda
Agenda Strengthening our competitiveness through innovation and partnerships Gustaf Salford, President & CEO Personalized precision and elevated productivity Maurits Wolleswinkel, Head of Linac and Software Solutions John Christodouleas MD, SVP Medical Affairs and Clinical Research Software driving
Slide 29: Oncology software must run clinics efficiently
Oncology software today must run clinics efficiently, legacy solutions of the day don’t solve for open and efficient ecosystems THEN – what legacy solutions are missing today NOW – what solutions need to solve today Learning and navigating multiple systems and interfaces provides an inefficient work
Slide 30: AI and big data solutions in radiation oncology
AI and big data solutions taking radiation oncology to new levels of operational performance and therapeutic precision. Smart Workflows Real World Outcomes Real World Outcomes Smart Workflows Tx Applications Smart view Plan Analytics Patient Companion Smart flow Planning Smart voice Complete Protoco
Slide 31: Collaborating with MIM evolves into broader partnership with GE Healthcare
Collaborating with MIM evolves into a broader partnership with GE Healthcare covering innovation and commercialization Partnership components at a glace Co-development Joint marketing and support OEM-agreement • MIM applications • Single brand in the market • Unified global go-to- replace and add to
Slide 32: Elekta ONE offers a strong commercial SaaS model
Elekta ONE offers a strong commercial SaaS model with significant value to customer with flexibility, accessibility, and ease of use ONE platform with all the solutions • Software packages with tiered functionality • Support the open software ecosystem • Streamlined workflow Customers always up to d
Slide 33: Increased SaaS focus brings commercial benefits and cost savings
Elekta’s increased SaaS focus brings commercial benefits, increased efficiencies, and cost savings to its business Long-term stable revenue and margin expansion SaaS share of total orders has • Increased value and revenue per customer – 80% revenue increase per increased to >20% currently customer c
Slide 34: Elekta ONE is resonating with customers
Elekta ONE is resonating with customers and already delivering positive impact to the patient's journey MOSAIQ recognized for radiation and medical oncology Positive testimonials across the Elekta ONE suite “Elekta ONETM | Plan Analytics Provides a suite of tools for curation and analysis that could
Slide 35: Elekta ONE model strengthens the long-term financial outlook
The Elekta ONE model strengthens the long-term financial outlook through stability, margin expansion and growth Financial outlook drivers from software Foundation Margin Growth Substantial installed base More value per customer Faster time to value Subscription stability & Focused investment agenda
Slide 36: Agenda
Agenda Strengthening our competitiveness through innovation and partnerships Gustaf Salford, President & CEO Personalized precision and elevated productivity Maurits Wolleswinkel, Head of Linac and Software Solutions John Christodouleas MD, SVP Medical Affairs and Clinical Research Software driving
Slide 37: Outline
Outline Trends in Europe Elekta’s position in Europe Impact of adaptive therapy Restricted Information and Basic Personal Data
Slide 38: Trends in the European radiotherapy market
Trends in the European radiotherapy market • Focus on personalized and adaptive treatments, efficiency is key • MR-Linac is becoming the first choice in most countries • Movement towards cloud • Combination treatments with increased focus on immunotherapy and radiotherapy Restricted Information and
Slide 39: Every other cancer patient needs radiotherapy
Every other cancer patient needs radiotherapy as part of their treatment – a foundational and complementary pillar of cancer care Usage % of Complementary patients to Radiotherapy? Radiotherapy ~50% Local Surgery ~45% treatments Alternatives that treat cancer locally and mainly affect the tumor and
Slide 40: Status market share Elekta in EU tenders – share gain!
Status market share Elekta in EU tenders – share gain! Last tenders being executed by EU resilience funds Poland Expected Takeaways Poland EU funds Italy 2022 currently being allocated • Elekta winning share “Concip” tender • Winning on solutions and Croatia 2024 services • Spain installments execut
Slide 41: Strong market position in Europe for Elekta
Strong market position in Europe for Elekta • Strong market share gain in Europe by complete solutions with strong service track record • Philips and MIM/ GE partnership showing impact for customers looking for adaptive AI driven solutions • Unity – an attractive solution to differentiate and drive
Slide 42: Online adaptive with versatile linac is a game changer in Europe
Personalized Precision Online adaptive with versatile linac is a game changer in Europe Image Quality Iris Elekta ONE | Online* *Elekta ONE | Planning, Planning Pro and Online are powered by MIM Restricted Information and Basic Personal Data
Slide 43: Welcome to Elekta booth
Welcome to Elekta booth >5,000 pre-booked customers visiting ESTRO= >1000 more compared to ESTRO 2023 >100 exhibitors Restricted Information and Basic Personal Data
Slide 44: Agenda
Agenda Strengthening our competitiveness through innovation and partnerships Gustaf Salford, President & CEO Personalized precision and elevated productivity Maurits Wolleswinkel, Head of Linac and Software Solutions John Christodouleas MD, SVP Medical Affairs and Clinical Research Software driving
Slide 45: Capital allocation going forward
Capital allocation going forward Dividends Selective Organic growth acquisitions AtDividends least 50% Investments in Selective opportunities in of net income technology leadership & technology and markets existing business Expanding portfolio, offering and market presence Restricted Information and
Slide 46: R&D investments to ensure technology leadership
R&D investments to ensure technology leadership to drive future financial performance Major innovations since FY19/20 R&D expenses Gross R&D as % of sales Gross R&D expenses (BSEK) ➢ Elekta Evo 12% ➢ CMM 10% ➢ Elekta One ➢ Elekta Esprit 2,177 ➢ Brachy Imaging Ring 1,473 ➢ Elekta Harmony 19/20 20/21
Slide 47: Gross margin challenges mainly due to external factors
Gross margin challenges in recent years mainly due to external factors … Gross margin development 19/20 - R12 Q3 23/24 Drivers of Gross Margin pressure Illustrative Inflation-driven cost increases • Material/components 42% A • Logistics • Salaries A Price pressure on existing platforms 38% B Mix eff
Slide 48: New innovations and cost efficiencies will improve gross margin
… however, new innovations and cost efficiencies will improve gross margin Gross margin expected future development from R12 Q3 23/24 Drivers of Gross Margin improvement Illustrative Volume growth A • Contribution from all business lines Improved price Pre-pandemic levels • Improved price points thr
Slide 49: Investments in our innovation pipeline are essential for the journey ahead
Investments in our innovation pipeline will be essential for a successful journey ahead Market share gains through technology leadership Leverage our installed base by increasing software and Driving service offerings supporting gross margin expansion shareholder value Revenue growth and Cash Flow c
Slide 50: Agenda
Agenda Strengthening our competitiveness through innovation and partnerships Gustaf Salford, President & CEO Personalized precision and elevated productivity Maurits Wolleswinkel, Head of Linac and Software Solutions John Christodouleas MD, SVP Medical Affairs and Clinical Research Software driving
Slide 51: Elekta @ ESTRO 2024
Elekta @ ESTRO 2024 New innovation Unity adoption Wins in Europe Margin expansion Restricted Information and Basic Personal Data 50
Slide 52: Hope for everyone dealing with cancer.
Hope for everyone dealing with cancer.
Slide 53: Elekta
CElekta